Medicine
Cancer Immunotherapy Resistance Mechanisms and Combination Strategies
Quick fact
More than half of patients with advanced cancers do not respond to immune checkpoint inhibitors like PD-1 blockers, and even among responders, about 30–50% eventually develop acquired resistance within a few years.
Why this is interesting
Imagine a cancer drug that unleashes the immune system to attack tumors—yet in many patients, it stops working. Why do tumors figure out how to escape the very immune army they once couldn't withstand?